1           The excitatory events that trigger 
myotonic action potentials in the absence of stabilizing
 
     2 slow afterdepolarization (AfD) that triggers 
myotonic action potentials.                             
 
     3                    Skeletal muscles from ADR 
myotonic animals show an increased number of oxidative f
 
     4 ncluding muscle histological morphology, and 
myotonic discharges and heart conduction abnormalities, 
 
     5 tal limbs of Tg26-hDMPK showed myopathy with 
myotonic discharges coupled with deficit in sarcolemmal 
 
     6 e sodium channel alpha-subunit, resulting in 
myotonic discharges in skeletal muscle of the lower urin
 
     7                                              Myotonic discharges were more common in statin-associate
 
     8 duction in the CUG(exp) mRNA, a reduction in 
myotonic discharges, a shift toward adult pre-mRNA splic
 
     9 ty and deactivation kinetics, and eliminated 
myotonic discharges.                                    
 
    10                                          The 
myotonic dystrophies (DM) are human diseases in which th
 
    11                       PURPOSE OF REVIEW: The 
myotonic dystrophies (DM1 and DM2) are the paradigm for 
 
    12  known RNA-mediated disorders, including the 
myotonic dystrophies and fragile X tremor ataxia syndrom
 
    13 tor protein that plays a pivotal role in the 
Myotonic Dystrophies and Huntington's Disease, and sever
 
    14                                              Myotonic dystrophies are the most common, comprising 28.
 
    15                   The pathomechanism for the 
myotonic dystrophies is not well understood and the role
 
    16 ansions of noncoding CUG and CCUG repeats in 
myotonic dystrophies type 1 (DM1) and DM2 cause complex 
 
    17                                              Myotonic dystrophies type 1 (DM1) and type 2 (DM2) are n
 
    18                                              Myotonic dystrophies type 1 and type 2 are progressive m
 
    19 tive approach to screening and management of 
myotonic dystrophies type 1 and type 2 requires a multid
 
    20 c mechanisms that have been proposed for the 
myotonic dystrophies, the clinical and molecular feature
 
    21 hat are specific to skeletal muscle, and the 
myotonic dystrophies.                                   
 
    22 c syndromes, with particular emphasis on the 
myotonic dystrophies.                                   
 
    23 e splicing and polyadenylation in congenital 
myotonic dystrophy (CDM).                               
 
    24 sion of a CTG repeat at the DM1 locus causes 
myotonic dystrophy (DM) by altering the expression of th
 
    25                                              Myotonic dystrophy (DM) is a genetic disorder caused by 
 
    26                                              Myotonic dystrophy (DM) is a multi-system neuromuscular 
 
    27                                              Myotonic dystrophy (DM) is a multisystemic disease cause
 
    28                                              Myotonic dystrophy (DM) is caused by a CTG expansion in 
 
    29                                              Myotonic dystrophy (DM) is caused by a triplet repeat ex
 
    30                                              Myotonic dystrophy (DM) is caused by either an untransla
 
    31                    The neuromuscular disease 
myotonic dystrophy (DM) is caused by microsatellite repe
 
    32                                              Myotonic dystrophy (DM) is caused by the expression of m
 
    33                                              Myotonic dystrophy (DM) is caused by two similar noncodi
 
    34  a topic of intense study due to its role in 
myotonic dystrophy (DM) pathogenesis.                   
 
    35           The RNA-mediated disease model for 
myotonic dystrophy (DM) proposes that microsatellite C(C
 
    36                                              Myotonic dystrophy (DM) type 1 is associated with an exp
 
    37 (MBNL) protein family has been implicated in 
myotonic dystrophy (DM), a specific function for these p
 
    38                                           In 
myotonic dystrophy (DM), expression of RNA containing ex
 
    39 t roles in muscle and eye development and in 
myotonic dystrophy (DM), in which expanded CUG or CCUG r
 
    40                                              Myotonic dystrophy (DM), the most common form of muscula
 
    41                                              Myotonic dystrophy (DM), the most common form of muscula
 
    42 proposed first for the neuromuscular disease 
myotonic dystrophy (DM), which is associated with the ex
 
    43                                              Myotonic dystrophy (DM)--the most common form of muscula
 
    44  is a key player in the disease mechanism of 
myotonic dystrophy (DM).                                
 
    45 tal muscle development and are implicated in 
myotonic dystrophy (DM).                                
 
    46 pathogenic event in the RNA-mediated disease 
myotonic dystrophy (DM).                                
 
    47 UGn RNA in the induction of stress in type 1 
myotonic dystrophy (DM1) cells and in the stress-mediate
 
    48                                              Myotonic dystrophy (DM1) is a highly variable, multi-sys
 
    49                                       Type I 
myotonic dystrophy (DM1) is caused by a triplet repeat e
 
    50                                              Myotonic dystrophy (DM1) is caused by an expansion of CU
 
    51                                           In 
myotonic dystrophy (DM1), both inactivation of musclebli
 
    52                                              Myotonic dystrophy (DM1), the most common muscular dystr
 
    53 ein implicated in the pathogenesis of type I 
myotonic dystrophy (DM1).                               
 
    54 ated with the degenerative muscular disease, 
myotonic dystrophy (DM1).                               
 
    55 ated with expanded repeat sequences, such as 
myotonic dystrophy (DM1).                               
 
    56                                           In 
myotonic dystrophy (dystrophia myotonica [DM]), an incre
 
    57 ls have been implicated in schizophrenia and 
myotonic dystrophy (MD), and both conditions carry an in
 
    58                                              Myotonic dystrophy 1 (DM1) is a multi-system disorder ch
 
    59                                              Myotonic dystrophy 1 (DM1) is a multisystemic disease ca
 
    60                                           In 
myotonic dystrophy 1 (DM1), aggregation of the mutant DM
 
    61 f skeletal muscle pathology in patients with 
Myotonic Dystrophy 1 (DM1).                             
 
    62                                              Myotonic dystrophy 2 (DM2) is a multisystem skeletal mus
 
    63                                              Myotonic dystrophy 2 (DM2) is an autosomal dominant, mul
 
    64 the results with those of four patients with 
myotonic dystrophy and 12 healthy individuals.          
 
    65 ely short triplet-repeat expansions found in 
myotonic dystrophy and Friedreich's ataxia confer varieg
 
    66 ween the pathogenic RNA repeat expansions of 
myotonic dystrophy and MBNL1.                           
 
    67                Using a cell culture model of 
myotonic dystrophy and myotonic dystrophy patient tissue
 
    68 ls are key players in both the human disease 
myotonic dystrophy and the regulation of alternative spl
 
    69 nic mouse model to show that derangements of 
myotonic dystrophy are reversed by a morpholino antisens
 
    70              This process is dysregulated in 
myotonic dystrophy because MBNL proteins are sequestered
 
    71  for a therapeutic strategy for treatment of 
myotonic dystrophy by ablating or silencing expression o
 
    72 sis might have a clinically relevant role in 
myotonic dystrophy cardiac conduction defects and pathol
 
    73 r generation of massive instabilities of the 
myotonic dystrophy CTG.CAG sequences.                   
 
    74                        The genetic lesion in 
myotonic dystrophy does not eliminate an essential muscl
 
    75 hanism of cardiac and muscle degeneration in 
myotonic dystrophy has been re-evaluated through a serie
 
    76                                  Research on 
myotonic dystrophy has led to the recognition of a novel
 
    77 unction is a prominent cause of mortality in 
myotonic dystrophy I (DM1), a disease where expanded CUG
 
    78  in the development of RNA splice defects in 
myotonic dystrophy I (DM1), we purified RNA-independent 
 
    79 s also responsible for the manifestations of 
myotonic dystrophy in non-muscle tissues.               
 
    80                                              Myotonic dystrophy is a complex neuromuscular disorder a
 
    81                  Therapeutic development for 
myotonic dystrophy is moving rapidly with the developmen
 
    82             RECENT FINDINGS: RNA toxicity in 
myotonic dystrophy is now associated with bi-directional
 
    83                   It now appears likely that 
myotonic dystrophy is the first instance of a genetic di
 
    84                                           In 
myotonic dystrophy it is the RNA rather than protein pro
 
    85 roteins HSP20, HSP25, alphaB-crystallin, and 
myotonic dystrophy kinase binding protein (MKBP) may reg
 
    86                                        MRCK (
myotonic dystrophy kinase-related Cdc42 binding kinase),
 
    87                                              Myotonic dystrophy kinase-related Cdc42-binding kinase (
 
    88 ation and invasion by binding and activating 
myotonic dystrophy kinase-related CDC42-binding kinase a
 
    89                 Caspase-mediated cleavage of 
myotonic dystrophy kinase-related CDC42-binding kinase-a
 
    90 cell culture model of myotonic dystrophy and 
myotonic dystrophy patient tissue, we have evidence that
 
    91 L1, a splicing factor that is sequestered in 
myotonic dystrophy patients by binding to expanded r(CUG
 
    92                          In human cells from 
myotonic dystrophy patients, treatment with 5-aza-CdR st
 
    93 e variant CaV1.1e in the skeletal muscles of 
myotonic dystrophy patients.                            
 
    94 sed Znf9 and Clc1 expression and rescued the 
myotonic dystrophy phenotype in Znf9+/- mice.           
 
    95 e Znf9 haploinsufficiency contributes to the 
myotonic dystrophy phenotype in Znf9+/- mice.           
 
    96 e basis for a new type of instability of the 
myotonic dystrophy protein kinase (DMPK) gene in patient
 
    97                                              Myotonic dystrophy protein kinase (DMPK), a muscle- and 
 
    98 G)n tract in the 3' UTR of the gene encoding 
myotonic dystrophy protein kinase (DMPK), which results 
 
    99 ' untranslated region of the gene coding for 
myotonic dystrophy protein kinase (DMPK).               
 
   100                 Abnormal expression of human 
myotonic dystrophy protein kinase (hDMPK) gene products 
 
   101 let-repeat expansion region from a truncated 
myotonic dystrophy protein kinase transcript mimic in vi
 
   102 -coil domain reminiscent of eukaryotic DMPK (
Myotonic Dystrophy Protein Kinase) family kinases such a
 
   103                By this mechanism, effects of 
myotonic dystrophy repeat expansions impact many differe
 
   104                             In both types of 
myotonic dystrophy the expanded repeat is transcribed an
 
   105  human samples from patients with congenital 
myotonic dystrophy type 1 (CDM1) and spinal muscular atr
 
   106  with Huntington's disease (CAG repeats) and 
myotonic dystrophy type 1 (CTG repeats).                
 
   107 anded rCUG and rCAG repeat RNAs expressed in 
myotonic dystrophy type 1 (DM1) and spinocerebellar atax
 
   108                                              Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are cau
 
   109 d CCUG are the underlying genetic causes for 
myotonic dystrophy type 1 (DM1) and type 2 (DM2), respec
 
   110  sequence is considered a causative agent of 
myotonic dystrophy type 1 (DM1) because of its ability t
 
   111 nscript (CUG(exp)) is the causative agent of 
myotonic dystrophy type 1 (DM1) by sequestering musclebl
 
   112 man spinocerebellar ataxia type 8 (SCA8) and 
myotonic dystrophy type 1 (DM1) CAG expansion transcript
 
   113  disease (HD) FEN1 +/- heterozygous mice and 
myotonic dystrophy type 1 (DM1) FEN1 +/- heterozygous mi
 
   114 A working hypothesis for the pathogenesis of 
myotonic dystrophy type 1 (DM1) involves the aberrant se
 
   115                                              Myotonic dystrophy type 1 (DM1) is a complex neuromuscul
 
   116                         The genetic basis of 
myotonic dystrophy type 1 (DM1) is a CTG expansion in th
 
   117                                              Myotonic dystrophy type 1 (DM1) is a CTG microsatellite 
 
   118                                              Myotonic Dystrophy type 1 (DM1) is a dominant neuromuscu
 
   119                                              Myotonic dystrophy type 1 (DM1) is a dominantly inherite
 
   120                                              Myotonic dystrophy type 1 (DM1) is a genetic disorder in
 
   121                                              Myotonic dystrophy type 1 (DM1) is a genetic disorder li
 
   122                                              Myotonic dystrophy type 1 (DM1) is a microsatellite expa
 
   123                                              Myotonic dystrophy type 1 (DM1) is a neuromuscular disor
 
   124                                              Myotonic dystrophy Type 1 (DM1) is a rare genetic diseas
 
   125                                              Myotonic dystrophy type 1 (DM1) is a triplet repeating d
 
   126                                              Myotonic dystrophy type 1 (DM1) is an autosomal dominant
 
   127                                              Myotonic dystrophy type 1 (DM1) is an autosomal dominant
 
   128                                              Myotonic dystrophy type 1 (DM1) is an inherited dominant
 
   129                                              Myotonic dystrophy type 1 (DM1) is an RNA dominant disea
 
   130                                              Myotonic dystrophy type 1 (DM1) is an RNA-dominant disea
 
   131                                              Myotonic dystrophy type 1 (DM1) is associated with expan
 
   132                                              Myotonic dystrophy type 1 (DM1) is caused by a CTG expan
 
   133                                              Myotonic dystrophy type 1 (DM1) is caused by a CTG expan
 
   134                                              Myotonic dystrophy type 1 (DM1) is caused by a CTG trinu
 
   135                                              Myotonic dystrophy type 1 (DM1) is caused by a CUGn expa
 
   136                                              Myotonic dystrophy type 1 (DM1) is caused by expansion o
 
   137                                              Myotonic dystrophy type 1 (DM1) is caused by expansion o
 
   138                                              Myotonic dystrophy type 1 (DM1) is caused by the expansi
 
   139                                              Myotonic dystrophy type 1 (DM1) is one of the most varia
 
   140                                              Myotonic dystrophy type 1 (DM1) is one such disorder tha
 
   141                                              Myotonic dystrophy type 1 (DM1) is the most common form 
 
   142 ion hypothesis for the CTG expansion causing 
myotonic dystrophy type 1 (DM1) located in the 3' noncod
 
   143             The disease mechanism underlying 
myotonic dystrophy type 1 (DM1) pathogenesis in skeletal
 
   144           Accumulation of RNA CUG repeats in 
myotonic dystrophy type 1 (DM1) patients leads to the in
 
   145                                           In 
myotonic dystrophy type 1 (DM1), dystrophia myotonica pr
 
   146  splicing has become a molecular hallmark of 
myotonic dystrophy type 1 (DM1), in which neonatal splic
 
   147 ough cataract is a characteristic feature of 
myotonic dystrophy type 1 (DM1), little is known of the 
 
   148  and GAA.TTC are integral to the etiology of 
myotonic dystrophy type 1 (DM1), myotonic dystrophy type
 
   149                                              Myotonic dystrophy type 1 (DM1), the most common form of
 
   150                                              Myotonic dystrophy type 1 (DM1), the most common form of
 
   151                                              Myotonic dystrophy type 1 (DM1), the most common muscula
 
   152                                              Myotonic dystrophy type 1 (DM1), the most prevalent musc
 
   153       In the hereditary degenerative disease 
myotonic dystrophy type 1 (DM1), transcripts from the mu
 
   154                                           In 
myotonic dystrophy type 1 (DM1), triplet repeat expansio
 
   155 date disease for RNAi therapy application is 
myotonic dystrophy type 1 (DM1), which results from toxi
 
   156 (hDMPK) gene products has been implicated in 
myotonic dystrophy type 1 (DM1), yet the impact of distr
 
   157 S; trisomy 21) and the dementia component of 
myotonic dystrophy type 1 (DM1).                        
 
   158 als with the inherited multisystemic disease 
myotonic dystrophy type 1 (DM1).                        
 
   159 ting symptom experienced by individuals with 
myotonic dystrophy type 1 (DM1).                        
 
   160 d pathogenic role of expanded CUG repeats in 
myotonic dystrophy type 1 (DM1).                        
 
   161 ocess is impaired in patients afflicted with 
myotonic dystrophy type 1 (DM1).                        
 
   162 rationally designed, multi-target agents for 
myotonic dystrophy type 1 (DM1).                        
 
   163 h are disrupted on loss of MBNL1 function in 
myotonic dystrophy type 1 (DM1).                        
 
   164 rophia myotonica protein kinase (DMPK) cause 
myotonic dystrophy type 1 (DM1).                        
 
   165    METHODS AND We selected 855 patients with 
myotonic dystrophy type 1 (women, 51%; median age, 37 ye
 
   166  cause dominantly inherited diseases such as 
myotonic dystrophy type 1 and 2 (DM1/2), Huntington's di
 
   167                           Friedreich ataxia, 
myotonic dystrophy type 1 and 3 forms of intellectual di
 
   168 detected in mouse models with DCM, including 
myotonic dystrophy type 1 and CELF1 overexpression model
 
   169 s previously characterized in the context of 
myotonic dystrophy type 1 and epithelial-to-mesenchymal 
 
   170 se sequences are involved in the etiology of 
myotonic dystrophy type 1 and Friedreich's ataxia, respe
 
   171                                              Myotonic dystrophy type 1 and type 2 (DM1 and DM2) are g
 
   172 ress in elucidating the disease mechanism in 
myotonic dystrophy type 1 and type 2.                   
 
   173                          Patients with adult 
myotonic dystrophy type 1 are at high risk for arrhythmi
 
   174 ng in the molecular and clinical features of 
myotonic dystrophy type 1 as well as the screening of cl
 
   175 epeats (CUG(exp)) are the causative agent of 
myotonic dystrophy type 1 by sequestering MBNL1.        
 
   176             Up to one-third of patients with 
myotonic dystrophy type 1 die suddenly.                 
 
   177                  Historically, patients with 
myotonic dystrophy type 1 have not received the medical 
 
   178                                              Myotonic dystrophy type 1 is an autosomal dominant disor
 
   179                                              Myotonic dystrophy type 1 is caused by the dysregulation
 
   180             Previous studies have shown that 
myotonic dystrophy type 1 is caused by the expansion of 
 
   181                  The average age of death in 
myotonic dystrophy type 1 is in the fifth decade.       
 
   182                                              Myotonic dystrophy type 1 is the most prevalent muscular
 
   183 he size of the CTG expansion in the blood of 
myotonic dystrophy type 1 patients is associated with to
 
   184 n contrast to the CUG-RNA hairpins formed by 
myotonic dystrophy type 1 repeats, we found no evidence 
 
   185 der than 18 years with genetically confirmed 
myotonic dystrophy type 1 who were admitted to the Neuro
 
   186   How this untranslated CTG expansion causes 
myotonic dystrophy type 1(DM1) has been controversial.  
 
   187                          Among patients with 
myotonic dystrophy type 1, an invasive strategy was asso
 
   188  nine had myotonic dystrophy type 2, one had 
myotonic dystrophy type 1, and 17 had no identified muta
 
   189 ples from individuals with one such disease, 
myotonic dystrophy type 1, provides an opportunity to pa
 
   190 f Friedreich ataxia, fragile X syndrome, and 
myotonic dystrophy type 1, respectively.                
 
   191  dementia, fragile X tremor ataxia syndrome, 
myotonic dystrophy type 1, spinocerebellar ataxia type 8
 
   192                                           In 
myotonic dystrophy type 1, the association between mutat
 
   193                                   Similar to 
myotonic dystrophy type 1, the poly(CUG)n RNA co-localiz
 
   194  atrophy, amyotrophic lateral sclerosis, and 
myotonic dystrophy type 1, were also reviewed.          
 
   195           Exon 2 is significantly reduced in 
myotonic dystrophy type 1, whose symptoms include dement
 
   196 uation, out of 1014 patients included in the 
Myotonic Dystrophy Type 1-Heart Registry between January
 
   197 ive diseases, such as Huntington disease and 
myotonic dystrophy type 1.                              
 
   198 tracts in the size range that is typical for 
myotonic dystrophy type 1.                              
 
   199 n abnormalities in the neuromuscular disease 
myotonic dystrophy type 1.                              
 
   200 06 adult patients with genetically confirmed 
myotonic dystrophy type 1.                              
 
   201  atrophy, amyotrophic lateral sclerosis, and 
myotonic dystrophy type 1.                              
 
   202 xpansions observed in human diseases such as 
myotonic dystrophy type 1.                              
 
   203  atrophy, amyotrophic lateral sclerosis, and 
myotonic dystrophy type 1.                              
 
   204  disorders, including Huntington disease and 
myotonic dystrophy type 1.                              
 
   205 er onset of symptoms and is less common than 
myotonic dystrophy type 1.                              
 
   206 en implicated in the cardiac pathogenesis of 
myotonic dystrophy type 1.                              
 
   207  myotonica protein kinase (DMPK) gene causes 
myotonic dystrophy type 1.                              
 
   208 able therapeutic target for the treatment of 
myotonic dystrophy type 1.                              
 
   209 ranslated CCTG expansion in an intron causes 
myotonic dystrophy type 2 (DM2) have uncovered a new typ
 
   210                                              Myotonic dystrophy type 2 (DM2) is a genetic disorder ch
 
   211                                              Myotonic dystrophy type 2 (DM2) is a multisystemic disor
 
   212                                              Myotonic dystrophy type 2 (DM2) is an incurable neuromus
 
   213                                              Myotonic dystrophy type 2 (DM2) is caused by a CCTG expa
 
   214                    The recent discovery that 
myotonic dystrophy type 2 (DM2) is caused by an untransl
 
   215                                              Myotonic dystrophy type 2 (DM2) is caused by the extreme
 
   216 ponsible for the massive expansions found in 
myotonic dystrophy type 2 (DM2) patients.               
 
   217  At some sites of repeat expansion, e.g. the 
myotonic dystrophy type 2 (DM2) tetranucleotide repeat e
 
   218 ribed but untranslated CCTG expansion causes 
myotonic dystrophy type 2 (DM2), along with other discov
 
   219 oops in r(CCUG)(exp), the causative agent of 
myotonic dystrophy type 2 (DM2), and are transformed int
 
   220 etiology of myotonic dystrophy type 1 (DM1), 
myotonic dystrophy type 2 (DM2), and Friedreich's ataxia
 
   221             Recently, it was discovered that 
myotonic dystrophy type 2 (proximal myotonic myopathy) i
 
   222 ofilm formation in Staphylococcus aureus and 
myotonic dystrophy type 2 in human, respectively.       
 
   223                                              Myotonic dystrophy type 2 is a genetic neuromuscular dis
 
   224                                              Myotonic dystrophy type 2 is caused by a (CCTG)/(CCUG)n 
 
   225  not well understood and the role of ZNF9 in 
myotonic dystrophy type 2 pathogenesis has not been full
 
   226                               In comparison, 
myotonic dystrophy type 2 tends to cause a milder phenot
 
   227              We explored this question using 
myotonic dystrophy type 2, a multisystemic disease thoug
 
   228 irst intron of the ZNF9 gene associated with 
myotonic dystrophy type 2, form slipped-strand DNA struc
 
   229 s, 34 had sodium channel mutations, nine had 
myotonic dystrophy type 2, one had myotonic dystrophy ty
 
   230 l mutations, chloride channel mutations, and 
myotonic dystrophy type 2.                              
 
   231                    The neuromuscular disease 
myotonic dystrophy type I (DM1) affects multiple organ s
 
   232                                              Myotonic dystrophy type I (DM1) exhibits distinctive dis
 
   233                                              Myotonic dystrophy type I (DM1) is a disabling multisyst
 
   234                                              Myotonic dystrophy type I (DM1) is a disabling neuromusc
 
   235                                              Myotonic dystrophy type I (DM1) is an RNA-mediated disea
 
   236        They contain CUG repeats, relevant to 
myotonic dystrophy type I, and CAG repeats associated wi
 
   237                   Molecular therapeutics for 
myotonic dystrophy will probably bridge the translationa
 
   238 ment for clinical screening of patients with 
myotonic dystrophy with proactive and systematic managem
 
   239 an skeletal actin (HSA)(LR) mice (a model of 
myotonic dystrophy) of various ages.                    
 
   240 ar ataxia, amyotrophic lateral sclerosis and 
myotonic dystrophy) that involve mutations within the an
 
   241 es of repeat instability and pathogenesis in 
myotonic dystrophy, a neurological disorder caused by an
 
   242  disease process raises the possibility that 
myotonic dystrophy, among genetic disorders, may be unus
 
   243 ts in Friedreich's ataxia, (CTG)n repeats in 
myotonic dystrophy, and (CGG)n repeats in fragile X synd
 
   244 , and 830 repeats of (CTG)n, which codes for 
myotonic dystrophy, and 130 and 600 repeats of (CGG)n, w
 
   245 sity in humans as may occur in, for example, 
myotonic dystrophy, and possibly, the metabolically obes
 
   246 leblind-like 1 (MBNL1), a gene implicated in 
myotonic dystrophy, as a robust suppressor of multiorgan
 
   247 s of European origin with PROMM and proximal 
myotonic dystrophy, from geographically distinct populat
 
   248 ated with multiple human diseases, including 
myotonic dystrophy, Fuchs endothelial corneal dystrophy,
 
   249        Many neurological diseases, including 
myotonic dystrophy, Huntington's disease and several spi
 
   250 AA)n, are associated with diseases including 
myotonic dystrophy, Huntington's disease, fragile X and 
 
   251 r phenotype reflects many of the features of 
myotonic dystrophy, including muscle histological morpho
 
   252  3' UTR mRNA reproduced cardinal features of 
myotonic dystrophy, including myotonia, cardiac conducti
 
   253                 In the best studied example, 
myotonic dystrophy, it appears that the main pathogenic 
 
   254 phasis on key updates in muscular dystrophy, 
myotonic dystrophy, mitochondrial myopathy, spinal muscu
 
   255 hronic progressive external ophthalmoplegia, 
myotonic dystrophy, neurofibromatosis type 2, and basal 
 
   256 d the pathobiology of disease mechanisms for 
myotonic dystrophy, spinal muscular atrophy, and fragile
 
   257                                           In 
myotonic dystrophy, the expression of expanded CUG repea
 
   258                                           In 
myotonic dystrophy, the lack of properly localized MBNL1
 
   259 rnative splicing and have been implicated in 
myotonic dystrophy, the most common form of adult onset 
 
   260 muscleblind function and the pathogenesis of 
myotonic dystrophy, we generated Drosophila incorporatin
 
   261 eases, including spinal muscular atrophy and 
myotonic dystrophy, where defects of splicing or alterna
 
   262 operties of potential therapeutic agents for 
myotonic dystrophy, which is caused by sequestration of 
 
   263                      In mammalian cells, the 
myotonic dystrophy-related Cdc42-binding kinase possesse
 
   264 ed and studied with respect to their role in 
myotonic dystrophy.                                     
 
   265 lular localization is a central component of 
myotonic dystrophy.                                     
 
   266 ead to muscle degeneration disorders such as 
myotonic dystrophy.                                     
 
   267 des to treat Duchenne muscular dystrophy and 
myotonic dystrophy.                                     
 
   268  skeletal actin, long repeat) mouse model of 
myotonic dystrophy.                                     
 
   269 ion disorders such as Huntington disease and 
myotonic dystrophy.                                     
 
   270  gene causes the autosomal dominant disorder 
myotonic dystrophy.                                     
 
   271 onduction delay, two predominant features of 
myotonic dystrophy.                                     
 
   272 bias seen in expanded CTG triplet repeats in 
myotonic dystrophy.                                     
 
   273 causes symptoms in the neuromuscular disease 
myotonic dystrophy.                                     
 
   274 bset of the cardiac dysfunctions observed in 
myotonic dystrophy.                                     
 
   275 ical diseases such as Huntington disease and 
myotonic dystrophy.                                     
 
   276 a potential drug target for the treatment of 
myotonic dystrophy.                                     
 
   277 sting a toxic RNA pathogenesis, as occurs in 
myotonic dystrophy.                                     
 
   278 e diseases, including Huntington disease and 
myotonic dystrophy.                                     
 
   279 uscle weakness and wasting characteristic of 
myotonic dystrophy.                                     
 
   280 disease severity and therapeutic response in 
myotonic dystrophy.                                     
 
   281  facioscapulohumeral muscular dystrophy, and 
myotonic dystrophy.                                     
 
   282 ssues, including heart failure, diabetes, or 
myotonic dystrophy.                                     
 
   283 hogenic feature of the neuromuscular disease 
myotonic dystrophy.                                     
 
   284 rdiac electrophysiological disease; one with 
myotonic dystrophy; and one with hypertrophic cardiomyop
 
   285                         Through breeding ADR 
myotonic mice with mice harboring a MEF2-dependent repor
 
   286 gnificantly reduced in skeletal muscles from 
myotonic mice.                                          
 
   287 ctivity of MEF2 was dramatically enhanced in 
myotonic muscles.                                       
 
   288                                              Myotonic muscular dystrophy (DM1) is the most common inh
 
   289                                              Myotonic muscular dystrophy (MMD) is an autosomal-domina
 
   290                                              Myotonic muscular dystrophy types 1 and 2 (DM1 and DM2, 
 
   291                             In addition, the 
myotonic mutations G200R and Y261C abolished potentiatio
 
   292 variable presentation that included proximal 
myotonic myopathy (PROMM) and type 2 DM (DM2) but withou
 
   293 ypertrophic cardiomyopathy with dysrhythmia, 
myotonic myopathy and hypotension, all distinctive muscl
 
   294 red that myotonic dystrophy type 2 (proximal 
myotonic myopathy) is also caused by a DNA expansion mut
 
   295 suggesting this may contribute to the end of 
myotonic runs.                                          
 
   296 on and fiber-type transformation observed in 
myotonic skeletal muscles.                              
 
   297  defects may increase excitability and cause 
myotonic stiffness or may render fibres transiently inex
 
   298 ks including myasthenia, periodic paralysis, 
myotonic stiffness, seizures, headache, dyskinesia, or e
 
   299                                              Myotonic syndromes include the non-dystrophic myotonias,
 
   300 cal manifestations and molecular genetics of 
myotonic syndromes, with particular emphasis on the myot